Drugs / Fosciclopirox
Fosciclopirox
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04608045 | May 2019 → Apr 2023 | neoplasm | CicloMed LLC | Completed | No outcome recorded |
| Phase 1 | NCT03348514 | Jan 2018 → May 2020 | cancer | CicloMed LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04956042 | Aug 2021 → Dec 2023 | acute myeloid leukemia | CicloMed LLC | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04525131 | Nov 2020 → Dec 2022 | urinary bladder cancer | CicloMed LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fosciclopirox | “Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following...” PMID 34059639 ↗ May 2021 |
| Known as | Ciclopirox Prodrug | “Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following...” PMID 34059639 ↗ May 2021 |
| Known as | Ciclopirox-pom | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802149 ↗ |
| Known as | CPX-POM | “Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following...” PMID 34059639 ↗ May 20211“Note: Fosciclopirox is the generic name for CPX-POM.” NCT03348514 ↗ |
| Modality | Small molecule | — CHEMBL4802149 ↗ |
| Route | Intravenous | “CPX-POM administered IV” NCT03348514 ↗ |